Is DBV Technologies S.A. (DBVT) a Buy, Sell, or Hold?
NASDAQ : DBVT
DBV Technologies S.A.
$15.5676 USD
-$0.14 (-0.91%)
- Volume
- 87.2K
- Average Volume
- 250.86K
- Market Capitalization
- $372.4M
- P/E Ratio
- -3.31
- Dividend Yield
- 0.00%
- Price Target
- $48.00
- Year High
- $26.19
- Year Low
- $8.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel Tassé |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DBVT |
| CUSIP | 23306J309 |
| CIK | 0001613780 |
| Web | https://www.dbv-technologies.com |
| Phone | 33 1 55 42 78 78 |
| Currency | USD |
| Employees | 161 |
| Country | FR |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.76 |
| Quick Ratio | 4.76 |
| Cash Ratio | 4.42 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 602.44 |
| Cash Flow | -1.78 |
| Price / Cash Flow | -3.57 |
| Price / Book | 6.60 |
Price Target and Rating
| Average Stock Price Forecast | $48.00 |
| High Stock Price Forecast | $51.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -67.57% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.7 |
| Trailing P/E Ratio | -3.31 |
| PEG Ratio | -0.19 |
| P/E Growth | -0.19 |
| Net Income | -$146.95M |
| Net Margin | -18636.77% |
| Pretax Margin | -18938.79% |
| Return on Equity | -130.06% |
| Return on Assets | -62.96% |
Financials Score
| AltmanZ Score | 0.35 |
| Piotroski Score | 3.00 |
| Working Capital | 194.9M |
| Total Assets | 266.4M |
| Ebit | -171.84M |
| Market Cap | 382.27M |
| Total Liabilities | 58.5M |
Poll Results
About DBV Technologies S.A. (NASDAQ:DBVT) Stock
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial vi ... rus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
2026-07-14 16:30:00
Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, July 16th, at 5:00 p.m.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
2026-07-06 16:30:00
AMF Regulated Information Châtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF relating to DBV Technologies shares (the “Liquidity Contract”). The Liquidity Contract is implemented in accordance with AMF Decision No.
2026-06-30 09:42:09
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
2026-06-29 16:00:00
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven years The objective of the detailed, iterative engagement was to ensure a complete, efficient, and timely FDA review of the BLA, once submitted The Agency has not requested additional data DBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026 DBV will host a conference call today, June 29, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today provided an update on the Biologics License Application (BLA) submission seeking marketing approval of the VIASKIN® Peanut Patch in children aged four through seven years. Over recent weeks, DBV has had ongoing detailed and iterative engagement with the U.S. Food and Drug Administration (FDA) with the objective of ensuring a complete, efficient, and timely review of the Company's upcoming BLA for children aged four through seven years.
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
2026-06-23 16:30:00
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the Company has been included in the Euronext Tech Leaders index. Inclusion in the index went into effect on June 22, 2026.
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
2026-06-15 09:01:12
DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-09 07:00:00
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference.
2026-06-08 16:35:00
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.
Frequently Asked Questions
-
What is the current DBV Technologies S.A. (DBVT) stock price?
-
DBV Technologies S.A.(NASDAQ:DBVT) stock price is $15.5676 in the last trading session. During the trading session, DBVT stock reached the peak price of $26.185 while $8.51 was the lowest point it dropped to. The percentage change in DBVT stock occurred in the recent session was --0.91% while the dollar amount for the price change in DBVT stock was -$0.14.
-
DBVT's industry and sector of operation?
-
The NASDAQ listed DBVT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DBVT?
-
Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs
Kevin Malobisky | Chief Operations Officer
James Briggs | Chief Human Resources Officer
Jonathan Neely | VP & Head of Investor Relations
Kevin Trapp | Chief Commercial Officer -
How many employees does DBVT have?
-
Number of DBVT employees currently stands at 161. DBVT operates from 177-181 Avenue Pierre Brossolette, Montrouge, None 92120, FR.
-
Link for DBVT official website?
-
Official Website of DBVT is: https://www.dbv-technologies.com
-
How do I contact DBVT?
-
DBVT could be contacted at phone #33 1 55 42 78 78 and can also be accessed through its website. DBVT operates from 177-181 Avenue Pierre Brossolette, Montrouge, None 92120, FR.
-
How many shares of DBVT are traded daily?
-
The average number of DBVT shares traded daily for last 3 months was 250.86K.
-
What is the market cap of DBVT currently?
-
The market value of DBVT currently stands at $372.4M with its latest stock price at $15.5676